All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
OE08018

Radionuclide precursors and radiopharmaceuticals for targeted radionuclide imaging and therapy

Public support

  • Provider

    Ministry of Education, Youth and Sports

  • Programme

    EUREKA - European co-operation in the sphere of applied and industrial research and development aimed at the support of multinational co-operation among industrial undertakings, research institutes and universities

  • Call for proposals

    EUREKA 6 (SMSM2008OE3)

  • Main participants

  • Contest type

    VS - Public tender

  • Contract ID

    1729/2010-32

Alternative language

  • Project name in Czech

    Radionuklidové prekurzory a radiofarmaka pro cílené radionuklidové zobrazení a terapii v nukleární medicině

  • Annotation in Czech

    Cílem navrhovaného projektu je vývoj technologií pro výrobu nových terapeutických radionuklidů a radiofarmak pro cílenou terapii (radioimunoterapii) na bázi peptidů a monoklonálních protilátek.

Scientific branches

  • R&D category

    AP - Applied research

  • CEP classification - main branch

    FR - Pharmacology and apothecary chemistry

  • CEP - secondary branch

    BG - Nuclear, atomic and molecular physics, accelerators

  • CEP - another secondary branch

    FD - Oncology and haematology

  • OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

    10304 - Nuclear physics<br>30104 - Pharmacology and pharmacy<br>30204 - Oncology<br>30205 - Hematology

Completed project evaluation

  • Provider evaluation

    V - Vynikající výsledky projektu (s mezinárodním významem atd.)

  • Project results evaluation

    Among other outputs, the methods for production of Y-90 and Lu-177 radionuclides for therapeutic use in oncology were developed. The most important practical output of the Project was the preparation of a new radioimmunotherapeutic tool, monoclonal antibody Nimotuzumab labeled with Lu-177. The preparation is aimed at treatment of cancers with high expression of epidermal growth factor receptors.

Solution timeline

  • Realization period - beginning

    Jan 1, 2008

  • Realization period - end

    Dec 31, 2011

  • Project status

    U - Finished project

  • Latest support payment

    Mar 2, 2011

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP12-MSM-OE-U/01:1

  • Data delivery date

    Jul 12, 2012

Finance

  • Total approved costs

    21,000 thou. CZK

  • Public financial support

    10,500 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    10,500 thou. CZK